Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight-loss drugs was intended to shut the door on that booming market. It hasn’t exactly worked out that way.

Novo Nordisk (NVO) won a key case Thursday to stop some compounding pharmacies from selling knockoff versions of ... active ingredient in diabetes drug Ozempic and weight-loss drug Wegovy ...

Where would you say Ozempic ranks in terms of ... which also opened the way for knockoff versions of the drugs to further erode Novo's market share. Jorgensen eventually resolved the manufacturing ...

News last week that a CNN investigative report found dozens of fake podcasts on the popular audio streaming and media service platform Spotify, illegally ...

Novo Nordisk (NVO) won a key case Thursday to stop some compounding pharmacies from selling knockoff versions of its blockbuster ... semaglutide — the active ingredient in diabetes drug Ozempic and ...

Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...